Investor sentiment has turned toward a steady bullish outlook. Main Street sentiment is also turning rapidly to embrace the idea that we are not on the verge of an imminent recession. Inflation has come all the way back down to near the Fed\u2019s target zone, and the Fed appears to be preparing for its last rate hike of the cycle later this month, according to Fed Funds Futures date from the CME.<\/p>\n
By all accounts, a new bull market is now well underway. But investor exposure remains shallow in the market. Now is the time to be on the hunt for new growth opportunities, especially among small caps that have yet to be discovered by the crowd.<\/p>\n
One interesting small cap on the Nasdaq, still trading under $2\/share but with growing sales and a growing brand footprint in an explosive growth market, is Mangoceuticals, Inc. (NASDAQ: MGRX).<\/p>\n
MGRX is a rising star in the men\u2019s health and wellness space, which is worth over $30 billion worldwide and is growing at a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. The stock is especially interesting because it has a unique angle on the ED market and has been on a rampage in terms of rising brand awareness but hasn\u2019t yet posted a breakout quarter that catches everyone\u2019s attention.<\/p>\n
In other words, it\u2019s still flying under the radar. But this earnings season could be the moment when everyone starts to take notice.<\/p>\n
Under the Radar, but Not for Long<\/strong><\/p>\n While shares of MGRX are still under the radar, the company\u2019s brand has been breaking out with a series of growth-oriented campaigns that act as part of its intense new focus to drive exponential sales growth in the quarters ahead.<\/p>\n Much of this has to do with high-profile marketing and public awareness exposure that the company has put together, and continues to expand, over the past couple of months. In that time, the CEO has rung the bell on the stock exchange on CNBC, been slated for appearances on Fox Business and Bloomberg TV, partnered with Gronk\u2019s Ice Shaker brand, and become a featured sponsor on Barstool Sports and the \u201cOnly Stans\u201d podcast sensation.<\/p>\n The company has also launched its \u201cMake America Hard Again\u201d campaign, which will be augmented by a dedicated web presence and a promise to the campaign into its other marketing efforts to drive a nationwide movement for men\u2019s health and wellness that feeds back into awareness around the company\u2019s products.<\/p>\n All of this follows the company\u2019s recently concluded successful IPO on the Nasdaq, which generated $5,000,000 in gross proceeds earmarked to fund product awareness and operational expansion as the company launches its flagship product: Mango, a groundbreaking solution designed to address men’s unique concerns.<\/p>\n In fact, not only is the launch of Mango already driving growth, but the company has already expanded its core ED offering to position itself for further market share penetration.<\/p>\n A Better Way<\/strong><\/p>\n Unlike competitors offering generic ED medications, Mangoceuticals takes pride in creating its own expertly formulated compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.<\/p>\n In other words, this is a disruptive model. Original Mango offers a special formulation featuring the same active ingredient as in Cialis™ (Tadalafil) along with other FDA approved ingredients to maximize results. And it\u2019s all packaged in a rapidly dissolving tablet that is absorbed orally and is capable of producing results in 15 minutes, with effects lasting up to 36 hours.<\/p>\n However, just a few weeks ago, the company announced the upcoming release of its second Mango ED product leveraging its existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra™. This one will also be delivered, like original Mango, in a rapidly dissolving mango-flavored tablet that activates and dissolves orally for immediate action.<\/p>\n The other interesting edge the company has is its unique telemedicine platform.<\/p>\n Mango is a prescription medication that must be approved by a physician. But the company has set up a telehealth infrastructure to aid in that process: After an individual has completed an online telehealth visit, MGRX\u2019s network of medical providers will review and approve a prescription if medically appropriate, and then send the product immediately to the customer.<\/p>\n Conclusion<\/strong><\/p>\n MGRX may well have the best-of-breed product in its space right now, delivering faster results, without the uncomfortable aspects of the process normally faced by ED patients.<\/p>\n At present, this is a cheap Nasdaq small cap with a disruptive angle targeting a $31 billion space growing at 15% CAGR. MGRX is packaging its unique strategy in a powerful vision with strong taboo-free messaging, and it\u2019s starting to get a lot of attention.<\/p>\n The company\u2019s commercial-stage operations are just starting to blossom. Once it adds clear signs of strong topline growth to this equation, investors may find they have to chase a new momentum favorite.<\/p>\n But all the pieces may already be in place now, while the stock is still flying under the radar. MGRX is worth a close look as the new bull market gets its legs.<\/p>\n","protected":false},"excerpt":{"rendered":" Investor sentiment has turned toward a steady bullish outlook. Main Street sentiment is also turning rapidly to embrace the idea that we are not on […]<\/p>\n","protected":false},"author":35,"featured_media":55537,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"stock_ticker":[16660,13648],"class_list":["post-73709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","stock_ticker-mgrx","stock_ticker-nasdaq","entry"],"acf":[],"yoast_head":"\n